The hunt for a hep B cure heats up, as An­tios Ther­a­peu­tics preps for an IPO

5 years ago
Financing

End­points ex­clu­sive: Bob Nelsen's Re­silience snags Flori­da CD­MO work­ing with the De­fense De­part­ment on Covid-19 ...

5 years ago
Deals

Jazz Phar­ma­ceu­ti­cals push­es to ex­pand la­bel on Xy­wav; FDA eyes Oc­to­ber for de­ci­sion on Seagen's lat­est ADC

5 years ago
News Briefing

Pa­trizia Cavaz­zoni named per­ma­nent di­rec­tor of CDER, adding to ques­tions around where Wood­cock will end up

5 years ago
People
FDA+

Covid-19 roundup: As­traZeneca's Farx­i­ga fails PhI­II test; Sup­ply deal for Eli Lil­ly's so­lo bam­lanivimab of­fi­cial­ly ...

5 years ago
Coronavirus

Gene ther­a­pies for neu­rode­gen­er­a­tive dis­eases: Pfiz­er, No­var­tis, Bio­gen and oth­ers seek more from FDA

5 years ago
Cell/Gene Tx
FDA+

Sage touts first win in $3B Bio­gen pact, but safe­ty pro­file, doubts over da­ta cloud road ahead

5 years ago
R&D

IPO mar­ket con­tin­ues to churn with a pair of Covid-19 biotechs seek­ing Nas­daq, while mi­to­chon­dria-fo­cused Re­neo ...

5 years ago
Financing
Coronavirus

Sanofi teams with vir­tu­al re­al­i­ty biotech on oral Dupix­ent suc­ces­sor

5 years ago
Deals
Discovery

Sanofi un­veils $476M vac­cine plant in Sin­ga­pore, bring­ing its to­tal out­lay to $1.7B in the field for past year

5 years ago
Deals
Manufacturing

Taysha Gene Ther­a­pies gears up to ap­proach reg­u­la­tors with a new can­di­date for a de­bil­i­tat­ing neu­rode­gen­er­a­tive ...

5 years ago
Deals
Cell/Gene Tx

Re­gen­eron’s Covid mAb as a pro­phy­lac­tic in­jec­tion: Re­duced risk of symp­to­matic in­fec­tion by 81%

5 years ago
Pharma
Coronavirus

AACR21: Eli Lil­ly blazes new trail for RET in­hibitor, gin­ning up a re­sponse in 9 sol­id tu­mor types in ear­ly da­ta

5 years ago
R&D
Pharma

AACR21: iTeos busts out ear­ly hu­man da­ta for an­ti-TIG­IT an­ti­body. Is it enough to match up with Roche, Mer­ck?

5 years ago
R&D

AACR21: Zen­tal­is keeps the heat on As­traZeneca with ear­ly WEE1 da­ta show­ing a group of 'ex­cep­tion­al' re­spon­ders

5 years ago
R&D

AACR21 roundup: Ar­cus rolls out PhI da­ta on adeno­sine block­er for CRC; Co­di­ak's en­gi­neered ex­o­some for IL-12 shows ...

5 years ago
R&D

AACR21: Bris­tol My­ers looks to build Op­di­vo's case in ear­ly can­cer with full da­ta in pre-sur­gi­cal NSCLC

5 years ago
R&D

AACR21: As­traZeneca un­veils next-gen PARP in­hibitor, look­ing to fol­low up on suc­cess of first-gen suc­cess sto­ry ...

5 years ago
R&D

AACR21: Sanofi rolls out new da­ta for ear­ly-stage 'non-al­pha' IL-2. Ear­ly feed­back? In­ter­est­ing, but most­ly meh

5 years ago
R&D

The End­points 20 un­der 40, biotech's new nor­mal, Stéphane Bancel's one re­gret, and more

5 years ago
Weekly

Sanofi CEO Paul Hud­son dives deep­er in­to mR­NA, buy­ing out an un­der-the-radar Fred Hutch spin­out

5 years ago
Deals

Biden’s bud­get wish list: Re­store the CDC, build a new NIH re­search cen­ter, pump in bil­lions to end the opi­oid and ...

5 years ago
Coronavirus

Lay­ing claim to an­oth­er AI 'first,' Ex­sci­en­tia tees up an I/O drug for the clin­ic

5 years ago
R&D
AI

John Robin­son re­cruits a small band of Ar­ray vets to kick­start dis­cov­ery at Co­gent; Syn­tim­mune co-founder takes ...

5 years ago
Peer Review
First page Previous page 709710711712713714715 Next page Last page
A service from the Financial Times